Natera (NASDAQ:NTRA) Price Target Raised to $200.00 at Guggenheim

Natera (NASDAQ:NTRA) had its price target hoisted by Guggenheim from $170.00 to $200.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. Guggenheim’s target price would suggest a potential upside of 18.69% from the stock’s previous close.

A number of other brokerages have also issued reports on NTRA. The Goldman Sachs Group lifted their target price on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Canaccord Genuity Group boosted their price objective on shares of Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Sanford C. Bernstein increased their target price on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. Robert W. Baird upped their price target on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Finally, Piper Sandler increased their target price on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, November 18th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $160.63.

Natera Price Performance

NASDAQ NTRA opened at $168.50 on Friday. The stock has a market capitalization of $22.25 billion, a P/E ratio of -95.74 and a beta of 1.65. The business’s fifty day moving average is $163.51 and its two-hundred day moving average is $133.77. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera has a 1 year low of $62.96 and a 1 year high of $183.00.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. During the same period in the prior year, the business earned ($0.95) EPS. The business’s revenue for the quarter was up 63.9% on a year-over-year basis. On average, research analysts forecast that Natera will post -1.61 earnings per share for the current fiscal year.

Insider Activity

In other Natera news, Director Gail Boxer Marcus sold 2,212 shares of the business’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $158.53, for a total transaction of $350,668.36. Following the sale, the director now directly owns 19,386 shares of the company’s stock, valued at $3,073,262.58. The trade was a 10.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Michael Burkes Brophy sold 608 shares of Natera stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $120.76, for a total value of $73,422.08. Following the transaction, the chief financial officer now owns 74,014 shares of the company’s stock, valued at $8,937,930.64. This represents a 0.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 123,409 shares of company stock valued at $20,045,631 in the last quarter. Company insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Natera

Hedge funds have recently added to or reduced their stakes in the business. Itau Unibanco Holding S.A. bought a new position in shares of Natera in the second quarter valued at about $28,000. Quarry LP boosted its stake in shares of Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares in the last quarter. Versant Capital Management Inc lifted its stake in Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares during the last quarter. Covestor Ltd grew its stake in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after buying an additional 95 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after buying an additional 106 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.